IP40
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments: Online Sales and Other Operations. It engages in the research and development of CBD loaded exosomes, as well… Read more
IP40 (IP40) - Net Assets
Latest net assets as of September 2025: €6.63 Million EUR
Based on the latest financial reports, IP40 (IP40) has net assets worth €6.63 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€11.12 Million) and total liabilities (€4.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €6.63 Million |
| % of Total Assets | 59.66% |
| Annual Growth Rate | -7.98% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 42.59 |
IP40 - Net Assets Trend (2021–2024)
This chart illustrates how IP40's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for IP40 (2021–2024)
The table below shows the annual net assets of IP40 from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €7.02 Million | +60.10% |
| 2023-12-31 | €4.39 Million | -29.54% |
| 2022-12-31 | €6.22 Million | -30.92% |
| 2021-12-31 | €9.01 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to IP40's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1029800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €40.08 Million | 775.60% |
| Total Equity | €5.17 Million | 100.00% |
IP40 Competitors by Market Cap
The table below lists competitors of IP40 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Little Green Pharma Ltd
AU:LGP
|
$14.26 Million |
|
PYRAMID TECHNOPLAST ORD (BSE)
NSE:PYRAMID
|
$14.27 Million |
|
Matahari Putra Prima Tbk
JK:MPPA
|
$14.28 Million |
|
IGM BIOSCIENCES DL-01
F:1K0
|
$14.29 Million |
|
artnet AG Namens-Aktien o.N.
XETRA:ART
|
$14.26 Million |
|
Akdeniz Yatirim Holding AS
IS:AKYHO
|
$14.25 Million |
|
Bersama Zatta Jaya
JK:ZATA
|
$14.25 Million |
|
Canfor Pulp Products Inc
PINK:CFPUF
|
$14.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IP40's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,103,000 to 5,167,000, a change of 1,064,000 (25.9%).
- Net loss of 1,834,000 reduced equity.
- New share issuances of 891,000 increased equity.
- Other factors increased equity by 2,007,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-1.83 Million | -35.49% |
| Share Issuances | €891.00K | +17.24% |
| Other Changes | €2.01 Million | +38.84% |
| Total Change | €- | 25.93% |
Book Value vs Market Value Analysis
This analysis compares IP40's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.35x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.64x to 3.35x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €2.37 | €3.88 | x |
| 2022-12-31 | €1.66 | €3.88 | x |
| 2023-12-31 | €1.00 | €3.88 | x |
| 2024-12-31 | €1.16 | €3.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently IP40 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.23%
- • Asset Turnover: 3.18x
- • Equity Multiplier: 1.79x
- Recent ROE (-35.49%) is above the historical average (-79.97%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -110.96% | -5126.02% | 0.02x | 1.39x | €-10.95 Million |
| 2022 | -58.87% | -147.09% | 0.37x | 1.09x | €-4.40 Million |
| 2023 | -114.55% | -34.41% | 1.97x | 1.69x | €-5.11 Million |
| 2024 | -35.49% | -6.23% | 3.18x | 1.79x | €-2.35 Million |
Industry Comparison
This section compares IP40's net assets metrics with peer companies in the Household & Personal Products industry.
Industry Context
- Industry: Household & Personal Products
- Average net assets among peers: $31,430,918,155
- Average return on equity (ROE) among peers: -2.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IP40 (IP40) | €6.63 Million | -110.96% | 0.68x | $14.26 Million |
| e.l.f. Beauty Inc (0EF) | $140.86 Million | 3.77% | 1.94x | $3.85 Billion |
| BaWang International (Group) Holding Limited (6BK) | $126.32 Million | -15.30% | 0.94x | $20.04 Million |
| Euglena Co. Ltd (8EG) | $10.83 Billion | -90.44% | 0.59x | $212.89 Million |
| POLA Orbis Holdings Inc (8PO) | $164.91 Billion | 5.63% | 0.21x | $675.68 Million |
| Pigeon Corporation (9N3) | $84.61 Billion | 9.89% | 0.28x | $1.04 Billion |
| edding AG (EDD3) | $50.20 Million | 17.25% | 0.96x | $15.72 Million |
| Henkel AG & Co. KGaA vz. (Pref Shares) (HEN3) | $2.81 Billion | 19.09% | 2.13x | $18.16 Billion |
| Hengan International Group Company Limited (HGNC) | $19.28 Billion | 16.98% | 1.19x | $1.98 Billion |
| Leifheit Aktiengesellschaft (LEI) | $111.34 Million | 12.73% | 1.14x | $83.09 Million |